MD Anderson researchers reported that success with off-the-shelf CAR T therapies depends on two measurable factors: pre-existing immune rejection and the intrinsic fitness of donor-derived CAR T cells. The study links immune biology before infusion and cell quality at the time of administration to downstream outcomes. The finding matters for commercialization because “universal” manufacturing models only hold if recipients maintain sufficient in vivo CAR T persistence. It also suggests patient stratification and manufacturing QC may be critical to reduce variability in efficacy for non-autologous cell products. No single drug name, trial identifier, or effect sizes were provided in the headline summary, but the mechanistic framing points to immunobiology as a key lever for improving consistent response rates.